Loading
Lung Cancer Research Studies / Neuroendocrine Tumor Research Advances · Journal article
International Journal of Molecular Sciences · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a retrospective, hypothesis-generating analysis of publicly available genomic data from pancreatic NETs that identifies associations between specific mutations (MEN1, DAXX, ATRX, TSC2) and chromosomal instability metrics (high FGA), and reports that FGA does not correlate with Ki67. The work raises potential avenues for prognostic refinement but provides no evidence of clinical utility, validation, or therapeutic benefit.
Retrospective secondary analysis of publicly available genomic databases. Pancreatic neuroendocrine tumor samples from cBioportal; specific eligibility criteria and cohort characteristics not detailed.
High Fraction Genome Altered (FGA) most prevalent in cases with MEN1 and DAXX or ATRX mutations TSC2 mutations significantly more prevalent in the high FGA group FGA did not correlate with Ki67 index
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This exploratory work does not establish actionable biomarkers or therapeutic targets. Clinicians should not alter management based on these associations; validation in prospective cohorts with clinical outcome correlation is required before any diagnostic or therapeutic application.
This is an exploratory genomic analysis of publicly available data identifying potential molecular subsets of pancreatic NETs, raising questions about prognostic stratification but lacking validation, clinical outcomes, or therapeutic testing.
As stated by the source record.
This exploratory work does not establish actionable biomarkers or therapeutic targets. Clinicians should not alter management based on these associations; validation in prospective cohorts with clinical outcome correlation is required before any diagnostic or therapeutic application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The natural history of pancreatic neuroendocrine tumors (NETs) can span decades of slow progression, but it is unpredictable, with a more aggressive course also being common. The two clinical biomarkers currently used to define the grade of a tumor, the Ki67 index and the mitotic index, are not able to fully capture the course of individual patients. This creates an unmet need to discover better prognostic biomarkers to inform therapeutic decisions, as well as therapies with overall survival benefit. Two genomic series of pancreatic NETs were examined to discover sub-sets with divergent characteristics. Primary data were downloaded from the cBioportal cancer genomics portal and analyzed at the individual sample level. Pancreatic NET patients without MEN1/DAXX/ATRX mutations were younger than NET patients with any of these mutations. Pancreatic NETs had consistently low tumor mutation burden but were heterogeneous in their Fraction Genome Altered (FGA), a metric of chromosomal instability (CIN), with one group presenting high FGA and another possessing low to intermediate FGA. FGA did not correlate with Ki67, but high FGA was most prevalent in cases with mutations in MEN1 and DAXX or ATRX. TSC2 mutations were significantly more prevalent in the group with high FGA.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.